Read by QxMD icon Read

Clinical Lung Cancer

Jose Pacheco, Paul A Bunn
The treatment landscape of small-cell lung cancer is rapidly evolving. Results of the first-line randomized trial comparing etoposide/carboplatin/placebo with etoposide/carboplatin/atezolizumab (IMpower-133) were recently published, showing a longer progression-free survival and overall survival for patients receiving atezolizumab. These results changed the standard first-line therapy for the first time in several decades. There are 4 additional ongoing randomized trials comparing chemotherapy alone with chemotherapy plus immune checkpoint inhibition as initial treatment...
January 2, 2019: Clinical Lung Cancer
Hiroshi Nokihara, Makoto Nishio, Noboru Yamamoto, Yutaka Fujiwara, Hidehito Horinouchi, Shintaro Kanda, Atsushi Horiike, Fumiyoshi Ohyanagi, Noriko Yanagitani, Linh Nguyen, Yifah Yaron, Anne Borgman, Tomohide Tamura
BACKGROUND: Cabozantinib inhibits tyrosine kinases including MET, AXL, VEGFR2, RET, KIT, and ROS1 and has demonstrated antitumor activity in multiple tumor types. The primary objective of this phase 1 study (NCT01553656) was to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of cabozantinib in Japanese patients. PATIENTS AND METHODS: Patients with advanced solid tumors were enrolled at 2 sites in Japan. After determining the MTD and RP2D, an expansion in non-small-cell lung cancer (NSCLC) consisting of 3 molecularly defined cohorts (EGFR mutation; KRAS mutation; ALK, RET, or ROS1 fusion) was initiated...
December 31, 2018: Clinical Lung Cancer
Buhai Wang, Ye Gao, Yuxiang Huang, Qiuxiang Ou, Tingting Fang, Chunhui Tang, Xue Wu, Yang W Shao
No abstract text is available yet for this article.
December 31, 2018: Clinical Lung Cancer
Bo Da Nam, Tae Jung Kim, Keunchil Park, Myung-Ju Ahn, Yoon-La Choi, Myung Jin Chung, Tae Sung Kim, Kyung Soo Lee
PURPOSE: To determine the outcomes of transthoracic rebiopsy for epidermal growth factor receptor (EGFR) mutation in patients with lung adenocarcinoma and to explore the clinical and procedure-related risk factors for the acquisition of nondiagnostic rebiopsy specimens. PATIENTS AND METHODS: We retrospectively reviewed 367 patients with lung adenocarcinoma who underwent transthoracic core needle biopsy for mutation analysis from September 2011 to October 2016. Of these, 199 patients underwent rebiopsy...
December 31, 2018: Clinical Lung Cancer
Jiyun Lee, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Yoon La Choi, Myung-Ju Ahn
INTRODUCTION: Non-small-cell lung cancer (NSCLC) patients harboring ALK or ROS1 rearrangements invariably acquire resistance to the first- and second-generation tyrosine kinase inhibitors (TKIs), most notably ALK G1202R and ROS1 G2032R. Lorlatinib, a novel third-generation TKI, produced remarkable results from the first-in-man phase 1 trial: an overall response rate of 46% and 50% for previously treated ALK- and ROS1-positive patients, respectively. However, the efficacy of lorlatinib has not been widely validated in Asian patients...
December 31, 2018: Clinical Lung Cancer
Alberto Cerra-Franco, Sheng Liu, Michella Azar, Kevin Shiue, Samantha Freije, Jason Hinton, Christopher R Deig, Donna Edwards, Neil C Estabrook, Susannah G Ellsworth, Ke Huang, Khalil Diab, Mark P Langer, Richard Zellars, Feng-Ming Kong, Jun Wan, Tim Lautenschlaeger
INTRODUCTION/BACKGROUND: Many patients with early stage non-small-cell lung cancer (ES-NSCLC) undergoing stereotactic body radiation therapy (SBRT) develop metastases, which is associated with poor outcomes. We sought to identify factors predictive of metastases after lung SBRT and created a risk stratification tool. MATERIALS AND METHODS: We included 363 patients with ES-NSCLC who received SBRT; the median follow-up was 5.8 years. The following patient and tumor factors were retrospectively analyzed for their association with metastases (defined as nodal and/or distant failure): gender; age; lobe involved; centrality; previous NSCLC; smoking status; gross tumor volume (GTV); T-stage; histology; dose; minimum, maximum, and mean GTV dose; and parenchymal lung failure...
December 29, 2018: Clinical Lung Cancer
Anand Narayanan, Friedrich D Knollmann, Julie Ann S Walby, Steffany Lim, David R Gandara, Jonathan W Riess
No abstract text is available yet for this article.
December 27, 2018: Clinical Lung Cancer
Yinyin Qin, Guoying Gao, Xiaohong Xie, Zheng Zhu, Weijie Guan, Xinqing Lin, Zhanhong Xie, Ouyang Ming, Rongchang Chen, Nanshan Zhong, Shiyue Li, Chengzhi Zhou
BACKGROUND: Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare subtype of lung cancer that is less reported and not well-understood. MATERIALS AND METHODS: We investigated the clinical features of 85 patients with PLELC to determine the prognostic factors. RESULTS: PLELC preferentially affected the young (71.8%) and nonsmokers (72.9%), without a significant difference in gender. Most (50.6%) patients were at the early stage with opportunity for operation, and patients at advanced stages mainly received multimodality treatment...
December 24, 2018: Clinical Lung Cancer
Vineeth Sukrithan, Jason Sandler, Rasim Gucalp, Richard Gralla, Balázs Halmos
No abstract text is available yet for this article.
December 24, 2018: Clinical Lung Cancer
Marie Darrason, Antoine Martin, Michael Soussan, Kader Chouahnia, Marie-Christine Pailler, Hanene Boudabous, Pierre-Yves Brillet, Guilhem Bousquet, Laurent Zelek, Boris Duchemann
Lymphoepithelioma-like carcinoma of the lung (LELC) is a rare, Epstein-Barr virus-associated tumor. LELC occurs mostly in young, Asian nonsmokers. A few hundred cases have been reported, mostly from retrospective Asian studies. Optimal treatment has not been clearly established. Treatment options are based on surgery for early stage and on cisplatin-based chemotherapy as first-line therapy for metastatic disease. Prognosis may seem better than for other types of non-small-cell lung cancer, but it remains poor in advanced disease, with a median survival of 24 months, and new treatments options are still warranted...
December 21, 2018: Clinical Lung Cancer
Wungki Park, Gilberto Lopes
There is a rising need for optimal biomarkers to better tailor treatments for patients with cancer in the era of immunotherapy. In addition to programmed death-ligand 1 (PD-L1) and tumor mutation burden (TMB), neutrophil-to-lymphocyte (NLR) is regaining interest as a biomarker in immunotherapy for its availability, accessibility, and reproducibility. High NLR, according to different thresholds, is consistently reported to correlate with poor prognosis in different treatments in several cancers. Yet, most data come from retrospective analysis, and proof of mechanism and principle evaluations are limited...
December 19, 2018: Clinical Lung Cancer
Michèle Beau-Faller, Matthieu Texier, Hélène Blons, Nicolas Richard, Fabienne Escande, Samia Melaabi, Sarab Lizard, Florence De Fraipont, Elisabeth Longchampt, Franck Morin, Gérard Zalcman, Jean-Pierre Pignon, Jacques Cadranel
INTRODUCTION: Evaluation of EGFR Mutation status for the administration of EGFR-TKIs in non-small cell lung Carcinoma (ERMETIC) was a prospective study designed to validate the prognostic value of EGFR/KRAS mutations in patients with advanced non-small-cell lung cancer (NSCLC), all receiving a first-generation tyrosine kinase inhibitor, erlotinib. ERMETIC2 was an ancillary project evaluating the clinical value of common EGFR/KRAS-mutated subclones regarding prognosis using highly sensitive molecular detection methods...
December 19, 2018: Clinical Lung Cancer
Lin Wang, Cheng Zhan, Jie Gu, Junjie Xi, Zongwu Lin, Liang Xue, Di Ge, Qun Wang
BACKGROUND: N2 disease represents a heterogeneous group of non-small-cell lung cancer (NSCLC) with varying 5-year overall survival (OS) rates. The skip N2 phenomenon is quite frequent, and its prognostic impact remains a matter of debate. The aim of this study is to further assess the clinical significance and prognostic value of skip N2 disease using propensity score matching. PATIENTS AND METHODS: The study cohort included 437 patients with stage pN2 NSCLC who underwent resection from 2005 to 2011...
December 19, 2018: Clinical Lung Cancer
Yalun Li, Rui Zhang, Yongzhao Zhou, Juan Song, Wenxin Luo, Panwen Tian, Weimin Li
No abstract text is available yet for this article.
December 19, 2018: Clinical Lung Cancer
Michael Schwarz, Florian Kocher, Dora Niedersuess-Beke, Jakob Rudzki, Maximilian Hochmair, Gerlig Widmann, Wolfgang Hilbe, Andreas Pircher
No abstract text is available yet for this article.
December 19, 2018: Clinical Lung Cancer
Claudio Vernieri, Diego Signorelli, Giulia Galli, Monica Ganzinelli, Massimo Moro, Alessandra Fabbri, Elena Tamborini, Mirko Marabese, Elisa Caiola, Massimo Broggini, Lital Hollander, Rosaria Gallucci, Giulia Vandoni, Cecilia Gavazzi, Tiziana Triulzi, Mario Paolo Colombo, Angela Maria Rizzo, Paola Antonia Corsetto, Giancarlo Pruneri, Filippo de Braud, Gabriella Sozzi, Valter Torri, Marina Chiara Garassino
Advanced lung adenocarcinoma with inactive liver kinase B1 (LKB1) tumor suppressor protein is associated with poor response to immune checkpoint inhibitors and molecularly targeted agents, and with dismal patient prognosis. LKB1 is a central orchestrator of cancer cell metabolism, and halts tumor growth/proliferation during metabolic stress. Recent preclinical evidence suggests that LKB1-inactive lung adenocarcinoma is highly sensitive to metformin, a safe and low-cost antidiabetic compound that inhibits mitochondrial oxidative phosphorylation...
December 19, 2018: Clinical Lung Cancer
Annelies Janssens, Sofia Derijcke, Daniëlle Galdermans, Marc Daenen, Veerle Surmont, Els De Droogh, Anneke Lefebure, Erika Saenen, Elke Vandenbroucke, Ann-Marie Morel, Anna Sadowska, Jan P van Meerbeeck
INTRODUCTION: Communication about the palliative setting remains a barrier for many physicians because they are afraid to harm the patient by giving bad news. We sought to determine whether this a valid concern; the influence of prognostic understanding on patients' quality of life (QoL); and which factors influence this relationship. METHODS: The present multicenter, cross-sectional study used a questionnaire to measure patients' prognostic understanding, QoL, mood, and coping strategy...
December 13, 2018: Clinical Lung Cancer
Laetitia Lambros, Arnaud Uguen
No abstract text is available yet for this article.
December 12, 2018: Clinical Lung Cancer
Hiroaki Akamatsu, Shunsuke Teraoka, Yasuhiro Koh, Takeharu Yamanaka, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Immune-checkpoint inhibitors (ICIs) play an important role in treatment for advanced non-small-cell lung cancer. Over one-half of patients, however, have relapse. Although rechallenge treatment of anti-cancer drugs that showed efficacy in prior lines of therapy has been broadly accepted in lung cancer, evidence of efficacy of rechallenge of ICIs has been limited to anecdotal case series. We therefore plan a phase II study. The primary endpoint is to assess the overall response rate of nivolumab in patients with advanced non-small-cell lung cancer who responded to prior ICIs...
December 11, 2018: Clinical Lung Cancer
Tao Jiang, Jing Zhao, Chao Zhao, Xuefei Li, Jiqiao Shen, Juan Zhou, Shengxiang Ren, Chunxia Su, Caicun Zhou, Mary O'Brien
BACKGROUND: There is an urgent need to develop a convenient and less invasive technique to monitor the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutated non-small-cell lung cancer (NSCLC). We proposed folate receptor-based assay to count circulating tumor cells (CTCs) to predict and dynamically monitor the therapeutic response to first-line EGFR-TKIs in patients with EGFR-mutated NSCLC. PATIENTS AND METHODS: Eligible patients were enrolled, and 3 mL of blood was obtained before initial treatment, 1 month after treatment, and every 2 months thereafter...
December 4, 2018: Clinical Lung Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"